^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-06446846

    i
    Other names: PF-06446846, PF846, PF06446846, PF-846, PF 06446846, PF 846
    Company:
    Pfizer
    Drug class:
    PCSK9 inhibitor
    Related drugs:
    2ms
    Dual-targeted albumin nanoparticles for the Co-delivery of low-dose paclitaxel and PCSK9 inhibitor in melanoma treatment. (PubMed, Mater Today Bio)
    We developed hyaluronic acid/R8-RGD dual-modified albumin nanoparticles (HR/LDPP-NPs) designed to co-deliver low-dose paclitaxel (PTX) and the PCSK9 inhibitor PF-06446846. This synergistic approach, combining in situ vaccination with enhanced antigen presentation, significantly amplifies antitumor immunity. Both in vitro and in vivo experiments demonstrate that these spatiotemporally coordinated dual-targeting nanoparticles achieve substantial therapeutic efficacy with significantly reduced toxicity, presenting a novel chemo-immunotherapeutic strategy for melanoma treatment.
    Journal • IO biomarker
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    paclitaxel • PF-06446846